Eli Lilly And Company
—- Market cap
- —
- Debt
- +$42.50B
- Cash
- −$7.27B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LLY stock price vs AXON: inconclusive — current versus $7.29K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AXON's multiple
Implied fair value · at LLY's multiple
Needs LLY P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 95% equity / 5% debt · EV / Revenue 14.26x · EV proxy / EBITDA proxy 1879.56x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Axon Enterprise, Inc. · implied price per share
Bear
$23.07
Base
$28.02
Bull
$34.69
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
LLY vs PFE
Merck & Co., Inc.
LLY vs MRK
Johnson & Johnson
LLY vs JNJ
AbbVie Inc.
LLY vs ABBV
Amgen Inc.
LLY vs AMGN
Bristol-Myers Squibb Company
LLY vs BMY
TYLER TECHNOLOGIES INC
LLY vs TYL
TELEDYNE TECHNOLOGIES INC
LLY vs TDY
LOCKHEED MARTIN CORP
LLY vs LMT
GENERAL DYNAMICS CORP
LLY vs GD
HUNTINGTON INGALLS INDUSTRIES, INC.
LLY vs HII
Howmet Aerospace Inc.
LLY vs HWM
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LLY can sustain its 44.7% revenue growth and 31.7% net margin, then hold or accumulate selectively because its profitability profile is much stronger than AXON's and the stock already sits within its historical trading band.
On a P/E basis, LLY trades far below AXON-implied price range and the model suggests very large upside, but that result is driven by AXON's exceptionally high 381.4x P/E rather than clear mispricing in LLY. LLY is also much closer to its historical band than to the DCF range, which implies the market is already valuing it near the upper end of historical expectations.
Supporting Metrics